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Global health   
1. Introduction 
Concomitantly with the start of the pandemic, the pursuit of effective 
vaccines began and developed with great success, and mass vaccination 
campaigns commenced by the end of 2020. The first quarter of 2021 saw 
countries such as Israel, the United Kingdom and the United States 
advancing at great pace in the vaccination programs, while other 
countries, mainly in the southern hemisphere, were just starting. By the 
beginning of April, 30 countries had not received a single dose and only 
0.57% of the African population was vaccinated [1]. The lag in the 
introduction of new immunization strategies between countries is not 
new. For example, in 2016, only 14% of the low- and middle-income 
countries (LMICs) had introduced the HPV vaccine in their national 
immunization plans, while 55% of high-income countries (HICs) had 
done so already [2]. Indeed, some vaccines have been introduced in 
LMICs years later than in HICs [3]. 
Despite the challenges posed by the unequal impact and the long 
duration of the pandemic, the introduction of a vaccine for the pre-
vention of COVID-19 has awakened feelings of hope in the global pop-
ulation. In this context, the Vaccine Global Access (COVAX) agreement 
was born as an initiative to ensure equitable global distribution of 
vaccines [4]. But even with this mechanism, there are multiple risks for 
unequal administration of the vaccines, so the greatest challenge now 
will be closing the gaps and mitigating the inequities in access to 
healthcare that have arisen [3,5,6]. 
Here we describe some of the barriers that contribute to unequal 
distribution of vaccines in LMICs (see Fig. 1). 
2. New nationalism 
Producing and distributing vaccines imply robust infrastructure and 
technological development, which is why they are usually manufactured 
in countries with greater resources [7]. The scenario where 
manufacturing factories are limited exposes a differential context be-
tween countries, which means that decisions can be taken unanimously 
in favour of the manufacturing country [8]. 
Many countries invested from the beginning to ensure the early de-
livery of vaccines to their population [8]. Companies also managed the 
commercial opportunity; for example, Sanofi proclaimed that the United 
States had the right to a greater batch of pre-purchased vaccines [9]. 
Similarly, several countries signed Advance Purchase Agreements with 
vaccine manufacturers to ensure their supply vaccines in early stages 
[10]. In fact, of the first 10 billion doses to be produced, half have been 
requested by countries of the European Union and five other countries 
only [11]. 
Other signs of this new nationalism are the closure of borders to 
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contain the spread of the virus [12] and the politically based delays in 
the distribution of vaccines [13], which affected citizens in different 
ways. The impact of border restrictions could be stronger after the 
implementation of mass vaccination by the use of "immunity passports" 
to ease restrictions on individuals who have acquired immunity [14]. 
Freedom of movement would be granted for residents of countries with 
greater resources to advance their vaccination campaigns, but it could 
also change the priorities in the order in which the population should be 
immunized, with corruption playing a role among those seeking to “skip 
the line” and creating a “two-tier” classification of citizens. 
3. Logistical challenges for the procurement and distribution of 
vaccines 
Immunization programs involve not only the purchase of vaccines, 
but also logistical challenges such as storage and transport [15]; the 
formulation of education and awareness strategies [3]; and integration 
with pre-existing vaccination programs in the population. 
The supply process of vaccines is complex, to the extent that logis-
tical issues must be anticipated. Requirements such as access to elec-
tricity and adequate equipment to keep vaccines at a certain 
temperature and at the required standards [15] is already challenging in 
a wide range of areas in LMICs. In the case of the SARS-CoV-2 vaccine, 
particularly Pfizer/BioNTech’s, storage at ultra-low temperatures is 
required, impeding access and distribution throughout vast countries 
with poor infrastructure [16]. 
Although there is no clear evidence that vaccine hesitancy is higher 
in persons of lower socioeconomic status, campaigns designed to deliver 
information about the vaccination rollout might be further challenged in 
LMICs. The success of a vaccination program will depend not only on 
logistical aspects, but also on beliefs, attitudes, knowledge and behav-
iour of the population (which may vary within and between countries) 
[3]. In this sense, all the evidence or, in certain cases, misinformation 
that has been created around certain vaccines can affect LMIC pop-
ulations and will not affect those already vaccinated [17]. 
Furthermore, countries with small healthcare capacity and coverage 
may also face challenges in identifying and contacting persons within 
high-risk groups that should be prioritized for vaccination. Data man-
agement and analytics can speed up rollout, optimize strategies in the 
chain of supply and track the impact of the vaccination process, but it 
requires a robust communication infrastructure [18]. This infrastructure 
and staff specifically trained for the vaccination program are also needed 
for critical regulatory areas and related functions to safeguard the 
quality, safety, and effectiveness of the vaccination effort [3]. Keeping 
up with the administration standards of more than 10 globally approved 
vaccines, each with different handling requirements [19], may be 
impossible, logistically and economically, for certain countries. 
4. Post-implementation challenges 
Another concern is the limited capacity to respond to possible 
adverse effects of vaccines. It is expected this could affect more people 
with lower economic income suffering from untreated diseases and risk 
factors [20]. Furthermore, vulnerable populations have limited access to 
healthcare services or to vaccination sites with all the resources to react 
appropriately to adverse reactions. In parallel, care costs relating to 
adverse events will have to be covered by the local healthcare system 
and not by the pharmaceutical companies, as stipulated in many existing 
contracts[5]. 
Likewise, there is the likelihood that continuous vaccination schemes 
will need to be maintained, given the duration of immunity and the 
possibility of new non-susceptible strains. The path that begins for the 
sake of health may be long and costly, and will requires arrangements at 
the international level that allow low-cost access in order to avoid 
leading poorer countries into more financial constraints and ensuring 
greater equity globally. In this sense, making regional alliances can be 
useful if they seek having common manufacturers for the production of 
vaccines at low cost, having patents approved more quickly or simply 
avoiding greater poverty and inequity at the global level. 
5. The role of global health 
Global health seeks to improve the health of the world’s population 
through various practices and the expansion of services for the com-
munity, especially in LMICs. This approach, although of key relevance, 
presents multiple challenges [21]. Projects that aim to reduce inequities 
in immunization, such as the WHO Global Vaccine Action Plan 
2011–2020 [22], have been slowly implemented and, in many cases, 
require HICs to achieve their vaccination goals before delivering vac-
cines to LMICs. Therefore, the reduction of inequalities between coun-
tries and region must be attempted utilizing alternative strategies. 
In response, partnership with other governments and non- 
governmental entities is fundamental, for example, the WHO Global 
Vaccine Blueprint Project [23], which has helped develop and imple-
ment a global support network to ensure minimum vaccine safety ca-
pacity, and the alliances for the achievement of vaccines, such as the 
COVAX alliance. Hand in hand, it is worth resuming those projects that 
sought to reduce the gaps between countries, which have decreased 
Fig. 1. Global challenges in the distribution of vaccines and implementation of vaccination plans against COVID-19.  
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since the COVID-19 outbreak [8]. 
Joint efforts have been seen in previous outbreaks, such as the HIV 
epidemic, to advocate for affordable drugs. Some activists have called 
for the lifting of patent restrictions granted to pharmaceutical com-
panies through agreements among World Trade Organization members. 
However, others argue that capacity building of vaccine production in 
LMICs is the real issue. This global crisis has further highlighted the need 
to establish facilities and technology transfer agreements in LMICs to get 
through this and future pandemics [24]. Only through enhancing LMICs 
and strengthening capacity development that reduces global in-
equalities, can the world be on the right path to a definitive solution to 
the current pandemic. 
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